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Background: Qing-Yi Decoction (QYD) has been used for severe acute pancreatitis (SAP) patients in China for many
years. There were two kinds of QYD: Num 1. QYD (QYD1) which is used in the acute response stage of SAP and
Num 2. QYD (QYD2) which is used in the second stage of SAP. This study aims to evaluate the therapeutic efficacy
of QYD in participants with SAP.
Methods: In this prospective, randomized, double-blind, placebo-controlled trial, participants aged 18–70 years
within the first 7 days after acute onset of typical abdominal pain (the definition of SAP was according to the
2007 Guidelines for Management of Severe Acute Pancreatitis in China) were selected. The disease severity was
determined by the Ranson, Acute Physiology and Chronic Health Evaluation II, and Balthazar CT scores. The test
group received Western medicine and Chinese medicine (Num.1 QYD and Num.2 QYD), while the control group
received Western medicine and placebo. The primary end-points were length of hospital stay, total hospitalization
expenses, operation rate, and mortality. The secondary end-points were organ complications (i.e., heart failure,
respiratory failure, acute renal failure, and hepatic failure), duration of paralytic ileus, infection, intensive care unit
stay, and respirator use.
Results: From March 2008 to July 2010, a total of 300 participants with severe acute pancreatitis were assessed for
eligibility in West China Hospital, and 100 were eligible for randomized allocation. Eighty-five participants (46 in the
test group; 39 in the control group) were included in the statistical analyses. The two groups were similar in their
baseline clinical characteristics (age, sex, and etiology) and disease severity. After the interventions, there were no
differences between the two groups for length of hospital stay (P = 0.323), total hospitalization expenses (P = 0.252),
operation rate (P = 0.231), mortality (P = 0.462), organ complications (P > 0.05), intensive care unit stay (P = 0.209),
and respirator use (P > 0.05). However, the duration [median (interquartile range)] of paralytic ileus, i.e., 4 (2–6) days
vs. 6 (4–8) days (P = 0.014) and rate of infection, i.e., (13.0 % vs. 35.9 %) (P = 0.013) differed significantly.
Conclusions: QYD could restore gastrointestinal motility to normal and reduce the infection rates in the SAP
patients who completed a full course of QYD treatment according to per protocol analysis.Background
The overall mortality rates of severe acute pancreatitis
(SAP) are approximately 15–30 % in worldwide [1], and
11.8–16.3 % in China [2, 3]. In patients with SAP, early
deaths primarily result from multisystem organ failure,
while late deaths primarily arise through complications
in patients with infected necrosis [4, 5]. Clinically,
gastrointestinal motility disorders, such as paralytic ileus,
abdominal pain, distension, and even intra-abdominal* Correspondence: xiaqing@medmail.com.cn
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unless otherwise stated.hypertension and abdominal compartment syndrome,
commonly encountered in the first stage of SAP are the
triggers for multiple organ failure [6]. Based on observa-
tions in pancreatitis models in animals, bacterial over-
growth and bacterial translocation were involved in the
pathogenesis of pancreatitis-induced sepsis [7]. Chinese
medicine (CM) active ingredients, such as emodin
(Dahuangsu), magnolol (Houpufen), naringin (Youpigan),
ginkgolide B (Yinxingneizhi), sanchinoside (Sanqizaogan),
taxol (Zishanfen), resveratrol (Baililuchun), rutoside (Yun-
xianggan), tetramethylpyrazine (Chuanxiongqin), and bre-
viscapine (Dengzhanhuasu), being used in treating SAPhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ach, and intestines, but also having marked treatment
effects on other visceral injuries arising from systemic
inflammatory responses accompanying pancreatitis and
blocking the disease progression [8].
CM has been used for the treatment of SAP patients in
China for several decades [9, 10]. In data collected from
West China Hospital for 1561 SAP patients between 1980
and 2005, it was found that patients who received a com-
bination of CM and Western medicine treatment had an
overall mortality of <10.25 % from 1994 to 2005 [11]. In
integrated CM and Western medicine therapy, the Chai-
Qin-Cheng-Qi Decoction (CQCQD), which is modified
from the Da-Cheng-Qi Decoction (DCQD) (Cortex Mag-
noliae Officinalis (Houpu), Fructus Aurantii Immaturus
(Zhike), Radix et Rhizoma Rhei (Dahuang), and Natrii
Sulfas (Mangxiao)), is widely used for acute pancreatitis
(AP) patients in China [12]. In the acute response stage,
both DCQD and CQCQD promoted the recovery of intes-
tinal mucosal permeability [13], improved intestinal par-
alysis, reduced intra-abdominal hypertension and length
of hospital stay [14], shortened the duration of gastro-
intestinal failure and secondary infections [15], reduced
AP-associated lung injury [16–18], improved gastric dys-
rhythmia, enhanced gastrointestinal motility, adjusted the
synchronized recovery of the alimentary tract, and in-
creased plasma ghrelin after abdominal surgery [19].
Qing-Yi Decoction (QYD) also modified from DCQD
has been used for SAP patients in China for many years.
Many Chinese studies showed that QYD can inhibit the
release of TNF-α and IL-8 to reduce inflammation of
rats with SAP [20, 21], was effective in treating experi-
mental SAP involved the MAPK and NLR signaling
pathways, cell cycle, metabolic pathways, and oxide
reductase activities [22]. QYD has two types: Num.1
Qing-Yi decoction (QYD1) is usually used in the acute
response stage of SAP patients for purgating heat and
bowels, dispersing stagnated liver qi; And Num.2 Qing-
Yi decoction (QYD2) is used in the second stage mainly
for clearing away heat and toxic material, promoting
blood circulation for removing blood stasis. Facing the
same disease, these two kinds of decoction focus on the
different emphases according to the different stages.
However, few prospective randomized controlled trials
(RCT) have been designed to determine the efficacy of
QYD. This study aims to conduct an RCT to evaluate
the therapeutic efficacy of QYD in treating SAP.
Methods
Study approval and registration
According to the Declaration of Helsinki and Good Clin-
ical Practice guidelines [23], the protocol was reviewed
and approved by the West China Hospital Ethics Com-
mittee, Sichuan University [2008(12)] (Additional files 1and 2). This trial was registered in the Chinese Clinical
Trials Register (Registration number: ChiCTR-TRC-
14004403). We reported the results in accordance with
the Consolidated Standards of Reporting Trials state-
ment [24].
Randomization and allocation concealment
Randomization sequence was performed with SAS soft-
ware (SAS Institute, USA) by two statisticians who were
not involved in the contact with participants. Sequentially
numbered sealed opaque envelopes containing allocation
codes were produced for allocation concealment by
coordinator in a separate location at the West China
Hospital. After recruitment of each participant and before
admission to any group, a numbered envelope was opened
at the location and a card inside only showed if the partici-
pant was to be in group A or group B. This information
was then given to the investigators. The coordinator was
not involved in the recruitment process for the study. The
recruitment investigators were not involved in the
randomization and allocation concealment process and
were blinded to the types of treatment received by the
participants. The participants involved also remained
unaware of the actual medications administered during
the entire study period.
Selection of participants
This trial was conducted at West China Hospital of Si-
chuan University (one of the largest treatment centers for
SAP in China) between March 2008 and July 2010. Three
hundred potential participants were contacted. They or
their representatives understood the study. A total of 236
participants provided written medical informed consent
prior to the clinical procedures (Additional file 3). All par-
ticipants were recruited and examined by investigators
according to the inclusion and exclusion criteria described
below.
The diagnosis of SAP was established on the basis of
acute onset of typical abdominal pain with at least three
times the upper limit of the reference range for serum
amylase or lipase, ultrasonographic or computerized tomo-
graphic (CT) scan evidence of pancreatitis, and an Acute
Physiology and Chronic Health Evaluation II (APACHE II)
score of ≥8, or a Balthazar CT score of ≥4, or a Ranson
score of ≥3 [25].
The inclusion criteria were: (a) all hospitalized adult
participants aged 18–70 years; (b) confirmed diagnosis
of SAP according to the 2007 Guidelines for Manage-
ment of Severe Acute Pancreatitis in China [25]; and (c)
participants within the first 7 days after acute onset of
typical abdominal pain.
The exclusion criteria were: (a) pregnant or lactating
women; (b) participants with malignancy; (c) participants
in a pre-death state (terminal phase of other diseases);
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ment prior to hospital admission.
Participants recruited into the trial were withdrawn if
they were lost to follow-up, refused enemas, dropped
out, or had serious adverse effects.
Clinical treatment
According to the 2007 Guidelines for Management of
Severe Acute Pancreatitis in China [25] and depending
on the disease severity and individual situations, two
groups were treated with the same Western medicine
treatment regimen, including fasting in the first several
days when participants still had severe abdominal pain,
gastrointestinal decompression, antacids, intensive organ
function monitoring, fluid resuscitation, maintenance of
water, electrolyte and acid–base balances, nutritional
supplements, and parenteral antibiotics (such as carba-
penems, quinolones, and metronidazole) for suspected
infections with microbiological evidence or clinical diag-
nosis. Assisted mechanical ventilation and intensive care
were performed if necessary. Participants with suspected
pancreatic infections were evaluated by an experienced
pancreatic surgeon. In addition, the participants in the
test group received CM therapy comprising QYD1 and
QYD2, while the participants in the control group
received placebo formulas made of dextrin that were
designed to resemble the QYD1 and QYD2 formulas in
their packaging, form, color, taste, size, and smell.
QYD1 was composed of Chaihu (Radix Bupleuri), 9 g;
Huangqin (Radix Scutellariae), 9 g; Chuanjizi (Fructus
Toosendan), 9 g; Yuanhu (Rhizoma Corydalis), 9 g;
Dahuang (Radix et Rhizoma Rhei), 15 g; Mudanpi (Cortex
Moutan), 9 g; Zhishi (Fructus Aurantii Immaturus), 9 g;
Houpo (Cortex Magnoliae Officinalis), 9 g; Mangxiao
(Natrii Sulfas), 10 g; and Gansui (Radix Kansui), 0.2 g.
QYD2 was composed of Chaihu (Radix Bupleuri), 9 g;
Huangqin (Radix Scutellariae), 9 g; Chuanjizi (Fructus Too-
sendan), 9 g; Yuanhu (Rhizoma Corydalis), 9 g; Dahuang
(Radix et Rhizoma Rhei), 30 g; Mudanpi (Cortex Moutan),
15 g; Hongteng (Caulis Sargentodoxae), 15 g; Baijiangcao
(Herba Patriniae), 15 g; Pugongying (Herba Taraxaci), 30 g;
Zihuadiding (Herba Violae), 30 g; and Taoren (Semen
Persicae), 9 g.
Schedule of administration in the test group: In the acute
response stage, each batch of QYD1 formula was divided
into two packages of granules weighing 10 g. Each package
of granules was dissolved in 200 mL of water, and adminis-
tered orally or intragastrically. After 1 h, two packages were
dissolved in 400 mL of water for enema performance. This
administration was performed every 6 h daily until the
participants’ bowel sound returned to normal. When the
participants’ abdominal pain disappeared, oral feeding was
encouraged. When participants were able to resume oral
feeding, each batch of QYD2 formula was divided into twopackages of granules weighing 10 g. Each package of gran-
ules was dissolved in 200 mL of water, and administered
orally three times daily rather than as an enema.
Schedule of administration in the control group: The
two placebo formulas were administered orally, intragas-
trically, or as an enema in the same manner as the QYD1
and QYD2 formulas in the test group. All prescribed
medications used in the two groups were prepared and
dispensed by an investigator in a separate room and not
involved in contact with participants.
Outcome measurements
The primary end-points were the length of hospital stay,
total hospitalization expenses, operation rate, and mor-
tality. The secondary end-points were organ complica-
tions [heart failure, respiratory failure, acute renal failure
(ARF), hepatic failure], incidence and duration of para-
lytic ileus, infection (pneumonia or pancreatic infection
diagnosed by microbiologic assessments), intensive care
unit (ICU) stay, and respirator use.
Monitoring and follow-up
All adverse events and compliance with the treatment
were recorded by a safety inspector throughout the study.
Clinical laboratory indexes, including routine blood, urine,
and stool tests, hepatic and renal functions, and electro-
cardiograms, were undertaken at baseline and once per
week after initiation of the treatment to assess the safety
for each group. If any emergencies occurred, the physician
investigators were notified to deal with them. After com-
pletion of the study, a minimum 1-month periodic out-
patient follow-up evaluation was performed by related
questionnaires (Additional file 4).
Statistical analysis
All data were analyzed using SAS statistical software (SAS
Institute, USA). All quantitative data were expressed as
mean and standard deviation (SD), percentage, or median
and interquartile range. A two-independent-sample t-test
was used to compare normally distributed data, while the
Wilcoxon rank sum test was applied for non-normally
distributed data. The Chi-square test was performed to
analyze categorical data. Values of P < 0.05 were con-
sidered statistically significant. Intention-to-treat (ITT)
(Additional file 5) and per-protocol analyses were both
performed. The two results were similar. As we intended
to exclude other factors and mainly focused on evaluating
the actual therapeutic efficacy of QYD instead of its safety,
finally per-protocol analysis was reported.
Results
Demographic data and baseline characteristics
A total of 300 participants with SAP were assessed for eligi-
bility from March 2008 to July 2010. Of these participants,
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age limitation; 30 were beyond the first 7 days after acute
onset of typical abdominal pain), 64 did not agree to par-
ticipate in the trial, and 85 met the exclusion criteria. In
total, 100 participants were eligible for randomization (50
in the test group; 50 in the control group). Four partici-
pants were withdrawn from the test group, because one
was lost to follow up and three refused to undergo enemas.
Additionally, 11 participants were withdrawn from the con-
trol group, because three were lost to follow up, three
refused to undergo enemas, and five dropped out. Finally,
there were 46 participants eligible for analysis in the test
group and 39 participants in the control group (Fig. 1).
The participants’ demographics and baseline clinical
characteristics in the two groups were summarized in
Table 1. The mean ages (SD) were 46.4 (11.3) years in
the test group and 44.6 (9.8) years in the control group.
The two groups had similar sex distributions. Hyperlip-
idemia was the most common etiology (56.5 % in the
test group vs. 38.5 % in the control group), followed by
gallstones, alcohol, and idiopathic factors in each group.
The Ranson scores [median (interquartile range)] in the
test group and control group were 3 (3–5) and 4 (3–5),
respectively. The APACHE II scores [median (interquar-
tile range)] evaluated within 24 h of admission were 10
(7.8–13) and 7 (5–13) in the test group and control
group, respectively. The Balthazar CT scores [median
(interquartile range)] were both 4 (4–6) in the test group
and control group. There were no differences in the
baseline characteristics in terms of age, sex, and etiology
between the two groups (P = 0.434, 0.805, 0.201, respect-
ively), or in the Ranson score (P = 0.608), 24-h APACHE
II score (P = 0.150), and Balthazar CT score (P = 0.118)
in the initial stage of administration.
Responses to treatment
Primary end-points
The comparisons of the primary end-points between the
two groups were shown in Table 2. The duration of hos-
pital stay [median (interquartile range)] in the two groups
did not differ significantly (P = 0.323), comprising 20
(14.8–27.3) days in the test group and 23 (16–28) days in
the control group. The total hospitalization expenses
[median (interquartile range)] did not differ significantly
between the two groups, being RMB33390.1 (24311.7–
45996.1) and RMB41523.1 (23216.0–68579.1) in the test
group and control group, respectively (P = 0.252). There
were no significant differences between the two groups for
the incidence of surgery (2.2 % vs. 7.7 %) (P = 0.231) or
mortality (2.2 % vs. 5.1 %) (P = 0.462).
Secondary end-points
The comparisons of the secondary end-points between
the two groups were shown in Table 3. The two groupsshowed no differences in the incidence and duration of
organ complications (P > 0.05), of which respiratory fail-
ure was the most prevalent complication, followed by
hepatic failure, heart failure, and ARF. There was also no
significant difference in the incidence of paralytic ileus
(P = 0.157): 95.7 % (44/46) in the test group and 87.2 %
(34/39) in the control group. Meanwhile, the durations
of paralytic ileus [median (interquartile range)] were 4
(2–6) days in the test group and 6 (4–8) days in the con-
trol group. The durations of ICU stay were both 0 (0–0)
days in the test group and in the control group. The res-
pirator usage rates were 8.7 % (4/46) and 23.1 % (9/39)
in the test group and control group, respectively. The in-
fection rates were 13 % and 35.9 % in the test group and
control group, respectively. Both the duration of para-
lytic ileus (P = 0.014) and the rate of infection (P = 0.013)
showed significant differences between the two groups.
Safety
One participant died in the test group and two partici-
pants died in the control group because of the severity
of SAP (discussed below). Diarrhea was the main adverse
event in this study, especially after taking QYD1 orally
and for enemas in the acute response stage. However,
diarrhea was also the main therapeutic pathway for SAP
patients to recover gastrointestinal function in CM.
Antidiarrheal agents were not allowed, as the mainten-
ance of water, electrolyte, and acid–base balances was of
great importance in this situation. No other adverse
events were reported in the two groups. In addition, no
significant changes were recorded in the laboratory
indexes or physical examinations.
Discussion
The participants with SAP in the test group receiving the
QYD1 and QYD2 formulas demonstrated significant im-
provements in the duration of paralytic ileus and the rate
of infections compared with the participants receiving the
placebo formulas in the control group. The other out-
comes such as length of hospital stay, total hospitalization
expenses, operation rate, mortality, organ complications,
ICU stay, and respirator use exhibited no significant differ-
ences between the two groups.
Paralytic ileus may cause endogenous bacterial over-
growth and increased gastrointestinal permeability and
intestinal ischemia, and promote bacterial translocation
from the intestine, thus resulting in systemic inflammatory
response syndrome, secondary infections, sepsis, multiple
organ dysfunction syndrome (MODS), and eventually
death [26, 27]. Thus, it is important to shorten the dur-
ation of paralytic ileus and recover gastrointestinal
function to reduce the risks of infection and mortality.
In our study, the QYD1 and QYD2 formulas effectively
decreased the duration of paralytic ileus and reduced the
Fig. 1 Flowchart of enrolled and randomized participants
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Table 1 Participant demographics and baseline clinical






Age (mean ± SD)† 0.434
Years 46.4 (11.3) 44.6 (9.8)
Sex, n (%)‡ 0.805
Male 26 (56.5) 21 (53.8)
Female 20 (43.5) 18 (46.2)
Etiology, n (%)‡ 0.201
Biliary 10 (21.7) 8 (20.5)
Hyperlipidemic 26 (56.5) 15 (38.5)
Alcoholic 4 (8.7) 4 (10.2)
Idiopathic 6 (13.1) 12 (30.8)
Scores (median (interquartile
range))§
Ranson’s score 3 (3–5) 4 (3–5) 0.608
24 h APACHE II score 10 (7.8-13) 7 (5–13) 0.150
Balthazar CT score 4 (4–6) 4 (4–6) 0.118
†Two independent samples t-test, ‡Chi-square test, §Wilcoxon rank sum test
APACHE II Acute Physiology and Chronic Health Evaluation II







Heart failure, n (%)‡ 12 (26.1) 12 (30.8) 0.633
Duration of heart failure, days
median (interquartile range)§
0 (0–1) 0 (0–2) 0.449
Respiratory failure, n (%)‡ 28 (60.9) 20 (51.3) 0.374
Duration of respiratory failure,
days median (interquartile range)§
1 (0–3) 1 (0–3) 0.835
ARF, n (%)‡ 5 (10.9) 3 (7.7) 0.617
Duration of ARF, days median
(interquartile range)§
0 (0–0) 0 (0–0) 0.715
Hepatic failure, n (%)‡ 11 (23.9) 15 (38.5) 0.147
Duration of hepatic failure, days
median (interquartile range)§
0 (0–0.3) 0 (0–4) 0.069
Paralytic ileus, n (%)‡ 44 (95.7) 34 (87.2) 0.157
Duration of paralytic ileus, days
median (interquartile range)§
4 (2–6)a 6 (4–8) 0.014
Infection, n (%)‡ 6 (13.0)a 14 (35.9) 0.013
ICU stay, days median
(interquartile range)§
0 (0–0) 0 (0–0) 0.209
Use of respirator, n (%)‡ 4 (8.7) 9 (23.1) 0.066
Use of respirator, days median
(interquartile range)§
0 (0–0) 0 (0–0) 0.067
‡Chi-square test, §Wilcoxon rank sum test. aP < 0.05 vs. control group
ARF acute renal failure
ICU intensive care unit
Chen et al. Chinese Medicine  (2015) 10:11 Page 6 of 8rate of infection. Meanwhile, one participant in the test
group died from respiratory failure on day 7 after onset
of abdominal pain. There was no evidence of infection
during the hospitalization. However, two participants in
the control group died as a result of MODS on days 14
and 32 after onset of abdominal pain. Further data
showed that one of these two participants had under-
gone surgery because of peripancreatic infection on day
21 after hospitalization, and died of secondary pulmon-
ary infection, bacillosis, and fungal sepsis. The other par-
ticipant had fungal sepsis, was transferred to the ICU on
day 12, and finally died of pyosepticemia. The effective-
ness of QYD1 and QYD2 demonstrated in this study
may occur primarily through improving intestinal par-
alysis, recovering the gastrointestinal function, and redu-
cing the bacterial translocation from the intestine,


















Operation, n (%)‡ 1(2.2) 3(7.7) 0.231
Mortality, n (%)‡ 1(2.2) 2(5.1) 0.462
‡Chi-square test, §Wilcoxon rank sum testof mortality. Despite these benefits, the other outcomes
examined, such as the length of hospital stay, total
hospitalization expenses, operation rate, mortality, organ
complications, ICU stay, and respirator use exhibited no
significant differences between the two groups, although
they generally tended to show decreasing trends.
In this study, hyperlipidemia was observed in nearly
half of the study subjects, followed by gallstones, alcohol,
and idiopathic factors in each group. This situation was
different from current findings that the most common
causes of AP are gallstones and alcohol [28]. In China,
gallstones remain the leading etiological factor for AP,
but the incidence of hypertriglyceridemia is increasing
[29]. Our results might arise through the eating habits of
the individuals who were included in the study. Most of
our participants came from Sichuan Province, where
people mainly eat the Sichuan cuisine, a diet notable in
Chinese cuisine for spicy, pungent, and greasy food. This
high-fat diet could easily result in hyperlipidemia.
The most important problem of this study was the
definition of SAP. This study used the 2007 Guidelines
for Management of SAP in China. The 2007 Guidelines
for Management of Severe Acute Pancreatitis in China
[25] was the latest definition at that time. The Atlanta
Classification of AP was revised in 2012 to provide a
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pancreatic conditions [30]. The recruitment of partici-
pants was completed in July 2010. We spent more than
one year on analyzing the data, writing and revising the
manuscript. In the future, we could re-analyze the data
according to the latest guideline retrospectively. Further-
more, owing to the limitations of the sample size, this
study was unable to determine the precise influences of
Qing-Yi Decoction on the length of hospital stay, total
hospitalization expenses, operation rate, mortality, organ
complications, ICU stay, and respirator use, especially
the influence on the incidence of surgery and mortality.
Conclusions
QYD could restore gastrointestinal motility to normal
and reduce the infection rates in the SAP patients who
completed a full course of QYD treatment according to
per protocol analysis.
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